sults show that plasma CRPlevelsdonot appear to predict risk of future venous thrombosis (twos tudies; N=41,308).F our studies(N=562) have examined the utility of plasma CRPinthe diagnosis of venous thrombosis;pooledp ositivea nd negative predictivevalues were 53% (95% CI:47%,59%)and 85% (95% CI: 81%,89%), respectively. Atwo-tosix-fold increase in the riskof deep vein thrombosis (DVT) is associated with elevationsi n plasma levels of CRP,IL-6, IL-8, MCP-1 orTNF-α (three studies). We can conclude that the natureofthe relationship between inflammation and clinical venous thrombosis is not yetestablished. CRPd oesn ot appear to be useful in predicting futurev enous thrombosis or in thed iagnosis of acute venous thrombosis. While several markersofinflammation areelevated in acute venous thrombosis,further research is needed to determine the preciserelationship between these markers andvenous thrombosis.T he identification and elucidationo fi nflammatory markersr elevant to venous thrombosis could providet argets forfuturetherapy.
Introduction
In recent years,aclear link hasbeen establishedbetween inflammation and the development of arterial atherothrombosis. For example, increased plasmalevelsofC-reactive protein (CRP), a predominant acute phase reactant and markerofinflammation, arepredictive of future myocardialinfarction and stroke (1) .
Inflammation mayalso playarole in venous thromboembolism (VTE),acommon thromboticvascular condition thataffects about 1/1000 peopleper year (2,3). Clinically,itisapparent that patients with deepveinthrombosis (DVT) manifest the four cardinal signs of inflammation, namely heat, redness, pain, and swelling. It is known thatthe procoagulant thrombin is capable of stimulating multiple inflammatoryp athways, and,e qually, inflammatory cytokines sucha si nterleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1are capable of activating coagulation (4, 5) . Lab studiesh aves hown that peripheral blood monocytes, when incubatedwith highly purified (>90%) human CRPf or 6h ours, exhibit as ignificant increase in procoagulant activity due to an increase in the expression of tissue factor,a ni nitiator of the extrinsic pathway of coagulation (6) . Animal studies have demonstrated that thrombosis directlyelicits an inflammatoryresponseinthe vein wall, whichinvolves neutrophil activation and expression of selectins, inflammatory cytokines,a nd cellular adhesion molecules ( 4, 7, 8) . Additionally, human saphenous vein endothelialcells have beenshown to increase secretion of IL-6a nd MCP-1 when incubatedw ith humanrecombinantCRP (9) .
In light of these observations,s everal clinical investigators have undertaken studies to attempt to elucidate the natureofthe relationshipbetween markers of inflammation and VTE. Theobjective of this paperi st oc ritically review and synthesize published clinical studiesthat have examinedthe link betweenthe inflammatoryresponseand VTE. We discuss the role of markers of inflammation in predicting future VTE,their utility in the diagnosis of VTE, and howtheir levels vary in response to VTE.
Methods
Medline wassearched in the English language forarticlespublished after 1980 using the keywords venous thrombosis,venous thromboembolism, inflammation, acutephase markers, C-reactive protein, interleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1. Search resultsw ere restrictedt oc linical humanstudies. Reviewarticlesand case reports were excluded. Bibliographiesofretrieved articleswere thensearched foradditional relevant articles.
Studies were too fewi nn umber and too heterogeneous to performformal metaanalysis with generation of summarystatistics. Hence, results are presented descriptively. Wherep ossible, pooled weightedindicesofaccuracy(e.g.sensitivity,specificity,predictive values) are presented.
Results

Markers of inflammationfor predicting futureVTE
Twop rospectives tudiesh avee xamined the predictive value of plasma CRP levelfor the development of VTE. ThePhysician's Health Study (1) enrolled22,071 U.S. male physicians between the ages of 40-84who had no historyofmyocardialinfarction, stroke, transient ischemic attack, or cancer. Study subjectswere followedfor up to 14 years.Mean plasma CRP levels in subjects whodeveloped VTEduring follow-up were 1.24 mg/l, compared with 1.10mg/l in subjects whodid not develop VTE(p=0.34). The lackofstatistical significanceofthese differencesmight be explained,atleastinpart, by the small number of participants in the studywho developedVTE (n=101). However, Tsai et al (10) also found that there wasnoassociation between baseline CRP levels and the subsequent development of VTE. Forthis analysis, those participants in the Cardiovascular Health Study (CHS)and the Atherosclerosis Risk In Communities (ARIC) study without prevalent VTE, ahistoryofcancer or useofwarfarinatbaseline were studied. Participants in the CHS studywere aged ≥ 65 years at entry,while those in the ARIC study were aged 45-64years at entry.Ofthe 19,237 patients in the pooled population, 159 patients developedVTE. Patients from the CHS and ARIC studies whodeveloped VTEhad mean (SD) plasma CRP levels (mg/l) of 4.0 ± 6.7 and 2.8 ± 2.4 respectively,vs. 3.6 ± 6.0 and 3.2 ± 5.9 respectivelyinthose whodid not develop VTE. Themeasured differences in plasma CRP levels were notstatistically significant in eitherstudy population (p=0.52inCHS and p=0.48 in ARIC). Furthermore, there were no differences in age-,r ace-and sexadjustedVTE incidencerates per 1000 person-years according to quartile of CRP levels. Overall, these results are consistent with those reported fort he Physician'sH ealth Study (1) and takentogether,indicate that plasma CRPlevelsdonot appear to predict future VTE events.
Elevatedplasma Factor VIII:C (FVIII:C) is arisk factor for VTE (11, 12) . Several studiesh avei nvestigated whether acute phase reactants cause this observedincrease in FVIII:C (13) (14) (15) and could therefore be predictive of future VTE. O'Donnell et al (13) investigated 45 patients in whom the sole risk factor for VTE wase levatedp lasma FVIII:C( >1.5 IU/ml). In these patients, therewere no significant correlations between FVIII:Cor FVIII:Ag levels and levels of the acutephase reactants CRPorfibrinogen. Subsequently, the same group seriallyinvestigated 35 patients whoh ad objectivelyc onfirmed VTE 3m onths -1 2 years earlier(median9months) and whose onlyVTE risk factor waselevatedplasma FVIII:C(≥ 1.5 IU/ml) (14) . Throughout follow-up (median 8m onths), 94% of patients continued to have elevatedl evelso fp lasma FVIII:C. Conversely, only6p atients hadelevatedlevelsofacutephase reactants (CRP ≥ 10 mg/mlor fibrinogen ≥ 4.0 mg/ml) at the beginning of the study,these persisted throughoutfollow-up in only3patients, and there wasno correlation between FVIII:Clevelsand acute phase reactant levels. Finally, Kamphuisen et al (15) conducted ac asec ontrol study of 474 patients with afirst episode of objectivelyconfirmed DVTa nd 474 age and sexm atched healthyc ontrols. Blood wasc ollectedi nc ases amedian of 18 monthsa fter the thrombotic event.Mean CRP levels were higher in thrombosis patients thanincontrols. After adjusting for CRPlevels, however, high factor VIII:C levels still increased the thrombosis risk 6-fold. Hence, based on the results of the above studies, it appears that the risk for VTE conferred by increased levels of FVIII:Cisnot caused by acutephase reactants such as CRP.
Markers of inflammationinthe diagnosis of VTE
The potential role of CRPi nt he diagnosis of VTE among patients with clinicallysuspected VTE has beenevaluatedinfour studies ( Table 1 ). All studies defined elevatedplasma CRP levels as >10 mg/l. Using contrastvenographyasagold standard,Thomas et al (16) tested whether plasma CRP levels were useful to diagnose deep venous thrombosis (DVT) in 47 patients with suspected DVT, 18 (38%)ofwhom were confirmed to have DVTon venography. ElevatedCRP levels hadasensitivity of 100%(95% confidencei nterval[ CI]7 8%-100%) and as pecificity of 52% (95% CI 34%-70%) for the diagnosis of DVT. The positive predictive value (PPV)a nd negative predictive value (NPV) were 56%and 100%, respectively,ascalculated fromthe data.These resultssuggestedthat non-elevatedCRP levels might be useful to excludeDVT in patients withclinically suspected DVT. However,several larger subsequent studiesbyW ong et al (17) ,Maskell et al (18) ,and Buceketal(19) have refuted thatplasma CRP levels are of value in the diagnosis of VTE(Table1). Combining the data from the fourstudies, allofwhich had asimilarprevalenceo fD VT in their study populations,y ieldedap ooled weighteds ensitivity of 77%,s pecificity of 66%, PPVo f5 3% and NPV of 85%. These resultsindicate that plasma CRPlevel, in itself,does not have utility for ruling in or ruling out DVTin patients with clinicallys uspected DVT. The potential role of other markersofinflammation in the diagnosis of VTE has not beenevaluated.
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Levels of markers of inflammationinacute VTE
Anumber of clinicalstudieshavemeasured levels of markers of inflammation in patients with DVTc ompared with controls without DVT(Table2). In acase-controlstudy,v an Aken et al (20) investigated whether elevatedp lasma levels (defineda s >90% control values) of the inflammatorycytokines IL-6, IL-8, and MCP-1 were associated with VTE. Plasma levels of these markers were measured in subjectswho had experienced at least 2VTE episodes betweenone and thirty years previously,compared with apparentlyh ealthyv olunteers. In patients with previous VTE, the odds ratio (OR) for elevatedplasma IL-6 was2.4 (95% CI 1.5-3.8), elevatedIL-8, 2.0 (95% CI 1.2-3.5), and elevated MCP-1, 1.9( 95% CI 1.2-3.2). Elevatedp lasma IL-8 was also shown to be associatedwith VTEinasecondcase-control study,also by vanAken, of 474 subjects with afirst episode of objectivelyconfirmed DVT(21) whow ere compared with 474 age and sex-matchedc ontrols whoh ad no historyo fVTE and were notb iologically related to the subjects( Leiden ThrombophiliaS tudy). IL-8 levels >90% control valuesw ere associated with an OR of 1.9(95% CI 1.2-2.8) and IL-8levels>99% control valuesw ere associatedw ith an OR of 6.0( 95% CI 2.0-17). The authorspostulatedthat because levels of inflammatorymarkers didnot differinpatients with recent VTE (less than 2years previously (20), or less than12months previously(21)) comparedt ot hose with more remote VTE (more than 9y ears previously (20), or morethan 28 months previously( 21)),i ti s possible that the inflammatorystate preceded the VTE, although this wasn ot directlye stablished.R eitsma and Rosendaal recently reported further on levels of inflammatorym ediatorsi n patients and controls from the Leiden Thrombophilia Study (22) . Tumor necrosis factor (TNF)-α ,IL-6 and IL-8 levels were found to be risk determinants for venous thrombosis,such that individuals with detectablelevelsofthese markers had OR thatranged from2-3 and those with levels >95% of control levels hadOR ranging from 2-5. Interestingly, high levels of the anti-inflammatoryc ytokine IL-10 were found to be protectivea gainst venous thrombosis.Roumen-Klappe et al (23) measuredlevelsof IL-6,IL-8 and CRPatthe timeofdiagnosis of acuteDVT and 5 days later.C onsistent with vanA ken'sa nd Reitsma'sr esults, plasma IL-8 levels were elevateda tb oth timep oints,h owever plasma IL-6 and CRP levels decreased fromDay 0toDay 5. This maybeanindication that inflammation is aconsequence rather than acauseofDVT (23) . The observeddecreaseinplasma IL-6 and CRP mayh aveb een partlya ttributablet ot he treatment regimen, as blood samples were takenduring the first 5daysof the studywhile the participants were being treated with heparin, whichhas anti-inflammatoryeffectsinrats (24) .
Prospective studiestoconfirmthese findings and help clarifythe sequence of eventswould be desirable.
Discussion
Of late, there has been agreat deal of research interest in the relation between mediatorsofthe inflammatoryreaction and cardiovasculardisease. ElevatedlevelsofCRP have beenshown to significantly increase the risk of clinical manifestations of atherosclerosis (1). In contrast, however, our reviewdid not find direct evidencetosupportthat markers of inflammation are predictive of future development of clinical venous thrombosis.T wo largeprospectivestudies(1, 10) comparedplasma CRP levels in people whodeveloped VTEtothose in people whodid not develop VTE, and both concluded thatp lasma CRP levels were not predictive of future development of VTE. Additionally,the risk for VTE conferredbyelevatedplasma FVIII:Cdoes not appear to be related to acute phase reactants (13) (14) (15) .Hence, atemporal association between markers of inflammation and the development of venous thrombosis has not yetbeen demonstrated.
We found indirect evidence, however, to supportt he view thatmarkers of inflammation suchasIL-6, IL-8, and MCP-1are involved in the pathogenesis of VTE. Three separate studies showedthat patients with VTE were morelikelytohaveelevated Based on the literaturep ublished to date,C RP,u seda lone, does not appear to be agood candidate for adiagnostic tool to detect or excludeVTE due to lowpositiveand negative predictive values (17) (18) (19) . The potentiallyl ethal consequences of VTE requirethat the negative predictive value of anysingle or combination of diagnostic tests be near1 00%. Further researchi s needed to determine whether other markers of inflammation could be of use as an adjunct to the currentlyavailablediagnostic tools in the detection of VTE.
In conclusion,the natureofthe relationshipbetween inflammation and clinical VTEhas notyet been elucidated. Effortsto associate CRP with VTEhavefailedtodemonstrate thatitcan eitherpredict future VTE or is useful in the diagnosis of VTE. However, recent research demonstrates ap robable association between VTEa nd several other markers of inflammation, notablyIL-6, IL-8 MCP-1and TNF-α being of particular interest. Overall, little has beenpublished in this area and further research is needed to determine the precise relationship between these markers of inflammation and VTE. Theidentification and elucidation of inflammatorymarkers relevant to VTE could provide targets for future therapy. Whether these markers maybeuseful in the diagnosis of VTEisasyet uncertain.
